Literature DB >> 10690401

Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required?

L Orlando, M Colleoni, F Nolè, R Biffi, A Rocca, G Curigliano, G Ferretti, G Peruzzotti, F de Braud, G Masci, A Goldhirsch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10690401     DOI： 10.1023/a:1008364801718

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  4 in total

1.  Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know.

Authors:  Davide Tassinari; Carlotta Santelmo; Paola Tombesi; Sergio Sartori
Journal:  Support Care Cancer       Date:  2008-01-16       Impact factor: 3.603

2.  Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter.

Authors:  Giuseppe Curigliano; Alessandra Balduzzi; Anna Cardillo; Raffaella Ghisini; Giulia Peruzzotti; Laura Orlando; Rosalba Torrisi; Silvia Dellapasqua; Loredana Lunghi; Aron Goldhirsch; Marco Colleoni
Journal:  Support Care Cancer       Date:  2007-06-20       Impact factor: 3.603

Review 3.  Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature.

Authors:  Jon C Anders; Perry W Grigsby; Anurag K Singh
Journal:  Radiat Oncol       Date:  2006-05-05       Impact factor: 3.481

4.  Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study.

Authors:  Luyuan Tan; Ya Sun; Liling Zhu; Xin Lei; Dongya Liang; Nanyan Rao; Fengxi Su; Kai Chen; Shunrong Li
Journal:  Cancer Manag Res       Date:  2019-09-13       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.